Repository logoGCRIS
  • English
  • Türkçe
  • Русский
Log In
New user? Click here to register. Have you forgotten your password?
Home
Communities
Browse GCRIS
Overview
GCRIS Guide
  1. Home
  2. Browse by Author

Browsing by Author "Sahin, I."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Article
    Does Hepatitis C Virus Infection Increase Hematocrit and Hemoglobin Levels in Hemodialyzed Patients
    (Dustri-Verlag Dr. Karl Feistle, 2003) Sahin, I.; Arabaci, F.; Sahin, H.A.; Ilhan, M.; Ustun, Y.; Mercan, R.; Eminov, L.
    Objective: Some case reports indicated that red cell status increased after hepatitis C viral infection. The aim of study was to define the influence of hepatitis C infection (HCV) on red cell status in hemodialyzed patients. Materials and methods: A total of 49 (21 anti-HCV-positive and 28 anti-HCV-negative) patients with ESRD were included in this study. Exclusion criteria were blood transfusion and massive blood loss in the last 6 months preceding the study. None of the patients used any drug containing aluminum. Results: The prevalence of anti-HCV antibody was 42.8%. Mean age was 51.6 ± 14.3 in anti-HCV (+) group and 50.4 ± 17.0 in anti-HCV (-) group. There was no statistically significant difference between the ages of the 2 groups. Mean duration time of hemodialysis was significantly longer in patients with anti-HCV antibody (+) group (54.9 ± 34.2 months) compared to anti-HCV-negative group (12.5 ± 9.0 months) (p < 0.001). Mean hemoglobin (Hb) and hematocrit (Htc) levels were significantly higher in anti-HCV-positive patients than in anti-HCV-negative patients (Hb: 10.4 ± 1.8 g/dl, Htc: 30.5 ± 5.5% vs Hb: 8.8 ± 1.7 g/dl, Htc: 26.1 ± 5.3%) (for Hb p < 0.005, for Htc p < 0.007). There was no significant difference regarding the usage of rHuEPO between the 2 study groups (57.1% in anti-HCV antibody (+)/59.3% in anti-HCV antibody (-)) (p > 0.05). All patients not receiving rHuEPO did so because of economical reasons. Serum AST and ALT levels were significantly higher in the anti-HCV antibody-positive group compared with the anti-HCV antibody-negative group. (AST p < 0.04, ALT p < 0.04). Conclusion: Anti-HCV antibody-positive ESRD patients have higher hemoglobin and hematocrit levels compared to HCV-negative patients.
  • Loading...
    Thumbnail Image
    Article
    Knowledge About Anaphylaxis and Using Auto-Injectable Adrenaline Among Physicians
    (Dustri-Verlag Dr. Karl Feistle, 2005) Onbasi, K.; Onbasi, O.; Sahin, I.
    Background: Physicians must possess knowledge of optimal acute management of anaphylactic/anaphylactoid reactions. Early and appropriate therapy is important. Recurrences may be prevented with education of patients, and using auto-injectable adrenaline may be life-saving. The purpose of the study was to assess physicians knowledge and attitude about these life-threatening events. Methods: A total number of randomly selected 93 physicians were asked to fulfill a questionnaire. A scenario about a patient developing life-threatening symptoms after receiving naproxen sodium tablet was described. The questionnaire consisted of basic treatment procedures about anaphylaxis and about the usage of auto-injectable adrenaline. Results: Only 50.5% of the physicians in our study answered that they would treat their patients with adrenaline in the case of anaphylaxis. Further evaluation revealed that only 23 of the 93 physicians (24.7%) knew the correct dose, correct form and the correct administration route. 89.2% of physicians did not know how to use an adrenaline auto-injector and 95.7% did never prescribe this device. Conclusion: Physicians knowledge about anaphylaxis/anaphylactic reactions in Turkey is not sufficient. Regular training courses should be advised. © 2005 Dustri-Verlag Dr. Karl Feistle.
Repository logo
Collections
  • Scopus Collection
  • WoS Collection
  • TrDizin Collection
  • PubMed Collection
About
  • Contact
  • GCRIS
  • Research Ecosystems
  • Feedback
  • OAI-PMH

Powered by Research Ecosystems

  • Privacy policy
  • End User Agreement
  • Feedback